Chinese researchers trial DREADD designer proteins in humans
TL;DR. Chinese neuroscientists began human trials of DREADDs, a gene therapy to control neuronal activity, for neurodegenerative diseases. - DREADDs are designer proteins that can be activated by specific drugs to either boost or suppress brain activity. - The research aims to explore DREADDs as a treatment for conditions like Parkinson's and Alzheimer's by modulating brain circuits. - US researchers express both scientific intrigue and ethical concerns regarding the rapid progression to human testing in China.
- Chinese researchers launched human trials for DREADDs (Designer Receptors Exclusively Activated by Designer Drugs).
- DREADDs are synthetic proteins designed to precisely control neuronal activity in the brain.
- The therapy aims to treat neurodegenerative diseases by 'turning down' overactive brain circuits.
- US neuroscientists are surprised by the speed of clinical application given the experimental nature of the technology.
- Potential for highly targeted brain modulation could offer new therapeutic avenues for complex neurological conditions.